Central Pharmaceuticals (DHA:CENTRALPHL) EPS (Basic): BDT-0.16 (TTM As of Mar. 2026)


DHA:CENTRALPHL Central Pharmaceuticals Ltd DHA:CENTRALPHL
61 GF Score
Price BDT9.90
GF Value BDT11.95
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Central Pharmaceuticals EPS (Basic)?

Central Pharmaceuticals DHA:CENTRALPHL +10.00% 61 EPS (Basic) is BDT-0.16 as of Mar. 2026. GuruFocus rates DHA:CENTRALPHL with a GF Score™ of 61/100 and a GF Value™ of BDT11.95 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Central Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was BDT-0.09. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-0.16.

Central Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was BDT-0.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT-0.17.

Central Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was BDT-0.09. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.15.

During the past 3 years, the average EPS without NRI Growth Rate was 37.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 33.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Central Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 58.90% per year. The lowest was -51.00% per year. And the median was -10.50% per year.

Central Pharmaceuticals  (DHA:CENTRALPHL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Central Pharmaceuticals EPS (Basic) Related Terms

Central Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Central Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceuticals EPS (Basic) Chart

Central Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.57 -0.37 -0.35 -0.18

Central Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 0.06 -0.07 -0.06 -0.09
DHA:CENTRALPHL
61GF Score
Central Pharmaceuticals Ltd DHA:CENTRALPHL
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Central Pharmaceuticals's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-21.982-0)/119.801
=-0.18

Central Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-10.43-0)/119.801
=-0.09

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of BDT-0.16 mean?
Central Pharmaceuticals (DHA:CENTRALPHL) has a EPS (Basic) of BDT-0.16 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Central Pharmaceuticals and its competitors.
Is Central Pharmaceuticals' EPS (Basic) too high?
Central Pharmaceuticals' current EPS (Basic) is BDT-0.16. Overall, Central Pharmaceuticals has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' EPS (Basic) compare to ZTS and UTHR?
Central Pharmaceuticals' EPS (Basic) of BDT-0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Central Pharmaceuticals and its competitors. Central Pharmaceuticals's current EPS (Basic) is BDT-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT11.95, compared to a current price of BDT9.90 — trading 17.2% below its estimated fair value. The current EPS (Basic) is BDT-0.16. Central Pharmaceuticals' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current EPS (Basic) is BDT-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued. The current stock price of BDT9.90 is trading 17.2% below its estimated GF Value™ of BDT11.95. GuruFocus considers Central Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for DHA:CENTRALPHL:

  • EPS (Basic): BDT-0.16
  • GF Value™: BDT11.95 vs. price of BDT9.90 (17.2% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Pharmaceuticals Business Description

Address South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
61GF Score

Get the complete analysis for DHA:CENTRALPHL

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT9.90
Price
BDT11.95
GF Value